Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Receivables: 2009-2025

Historic Receivables for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $297.7 million.

  • UNITED THERAPEUTICS's Receivables fell 12.90% to $297.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 4.89%. This contributed to the annual value of $279.3 million for FY2024, which is 0.14% up from last year.
  • Latest data reveals that UNITED THERAPEUTICS reported Receivables of $297.7 million as of Q3 2025, which was down 21.51% from $379.3 million recorded in Q2 2025.
  • UNITED THERAPEUTICS's 5-year Receivables high stood at $379.3 million for Q2 2025, and its period low was $134.5 million during Q1 2023.
  • In the last 3 years, UNITED THERAPEUTICS's Receivables had a median value of $290.7 million in 2024 and averaged $287.5 million.
  • Per our database at Business Quant, UNITED THERAPEUTICS's Receivables dropped by 21.11% in 2023 and then surged by 128.48% in 2024.
  • Over the past 5 years, UNITED THERAPEUTICS's Receivables (Quarterly) stood at $198.7 million in 2021, then rose by 10.92% to $220.4 million in 2022, then grew by 26.54% to $278.9 million in 2023, then rose by 0.14% to $279.3 million in 2024, then decreased by 12.90% to $297.7 million in 2025.
  • Its Receivables stands at $297.7 million for Q3 2025, versus $379.3 million for Q2 2025 and $322.0 million for Q1 2025.